Colorectal Cancer
Advertisement
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
Experts speak on the new face of CRC, the potential mechanisms for these trends, and how CRC screening programs should react.
Dr. Tie discusses the beneficial results seen with a ctDNA-guided approach, and touches on its role in future trials.
Dr. James Cleary discusses the use of HER2-directed therapies for the treatment of CRC.
Dr. Ashwin Somasundaram discusses the results of a recent phase 2 study of ipilimumab, nivolumab, and panitumumab for mCRC.
CheckMate-8HW remains in progress to determine secondary end points such as overall survival.
Low-dose aspirin halved recurrence in resected PIK3CA-mutated colorectal cancer, per data from the ALASCCA trial.
Dr. Michael Foote breaks down the CheckMate 8HW trial and supports dual immunotherapy as a first-line option in dMMR CRC.
Dr. Foote discusses the BREAKWATER trial and the impact of BRAF-targeted therapy in metastatic colorectal cancer.
Sassun-Mayo N/TNM staging demonstrated superior OS stratification compared with current AJCC staging.
Dr. Eng discusses the rising global incidence of early-onset CRC, as highlighted in a recent Lancet Oncology publication.
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
The guideline was developed using a multidisciplinary team of oncologists in collaboration with ASCO and the SUO.
ctDNA can serve as a major independent prognostic biomarker in patients with stage III colon cancer after surgery.
The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.
With an OS rate of about 80%, encorafenib and cetuximab with FOLFOX may serve as a new FDA-approved frontline regimen.
Encorafenib with cetuximab was approved by the FDA in 2024 for previously treated patients with BRAF V600E-mutant mCRC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.